Literature DB >> 6827912

Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs.

S V Otton, T Inaba, W Kalow.   

Abstract

Testing for competitive inhibition of sparteine oxidation in the 9000 x g supernatant fraction from human liver provides an in vitro means to identify drugs which can bind to the same form of cytochrome P450 which oxidizes sparteine. There has so far been only two outcomes of this test: either the drug examined competed with sparteine for a common binding site, or it did not inhibit the reaction. The results of such in vitro testing implicated the involvement of guanoxan, nortriptyline, desipramine, imipramine, amitriptyline and chlorpromazine with this enzyme. Amobarbital, tolbutamide and guanethidine in therapeutic concentrations did not interfere with sparteine oxidation by this preparation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6827912     DOI: 10.1016/0024-3205(83)90315-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  21 in total

1.  Pharmacological and toxicological significance of brain cytochromes P450.

Authors:  V Ravindranath
Journal:  Neurotox Res       Date:  2001-08       Impact factor: 3.911

2.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

3.  Substantial rise in sparteine metabolic ratio during haloperidol treatment.

Authors:  L F Gram; D Debruyne; V Caillard; J P Boulenger; J Lacotte; M Moulin; E Zarifian
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

4.  Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.

Authors:  G Mikus; H R Ha; S Vozeh; C Zekorn; F Follath; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).

Authors:  J Pressacco; R Muller; W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  High affinity of quinidine for a stereoselective microsomal binding site as determined by a radioreceptor assay.

Authors:  S V Otton; W Kalow; P Seeman
Journal:  Experientia       Date:  1984-09-15

7.  The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.

Authors:  T Ebner; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

8.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

Authors:  H K Crewe; M S Lennard; G T Tucker; F R Woods; R E Haddock
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

10.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

Authors:  D Wu; S V Otton; B A Sproule; U Busto; T Inaba; W Kalow; E M Sellers
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.